1ISG-003 Cost saving in antiretroviral therapy through breaking fixed-dose combination and switch to generic formulations

BACKGROUND: The commercialisation of fixed-dose combination meant an improvement in antiretroviral therapy (ART). With generics we have the opportunity to maintain the therapy at a lower cost, but we complicate the dosage regimen again. PURPOSE: To assess the effect in costs of a two-pill, generic-b...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Eur J Hosp Pharm
Main Authors: Molina, M Bullejos, Delgado, C Romero, Aller, T Virgos, Gomez, G Calzado, Eguior, N Yurrebaso, Campos, M Perez, Ponsjoan, S Gonzalez, Casariego, J Nazco
Format: Artigo
Jezik:Inglês
Izdano: BMJ Group 2018
Teme:
Section 1: Introductory statements and governance
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535606/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.3
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki